Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia

Children's Oncology Group

Status

Completed

Conditions

Leukemia

Treatments

Other: medical chart review

Genetic: protein expression analysis

Genetic: western blotting

Other: flow cytometry

Other: laboratory biomarker analysis

Study type

Observational

Funder types

NETWORK

NIH

Identifiers

NCT01245231

CDR0000689410 (Other Identifier)

COG-AAML11B6 (Other Identifier)

NCI-2011-02845 (Registry Identifier)

AAML11B6

Details and patient eligibility

About

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is studying prognostic biomarkers in cell samples from young patients with acute myeloid leukemia.

Full description

OBJECTIVES:

Primary

To determine the percentage of primary acute myeloid leukemia (AML) samples with increased Stat3 signaling pathway activity.
To evaluate the presence of constitutive Stat3 activation and the sensitivity of Stat3 activation to low- and high-doses of cytokines.
To evaluate the expression levels of Stat3 protein and the upstream and downstream regulators of Stat3 activation.

Secondary

To classify samples according to a Stat3 activation pattern and correlate this result with event-free survival (EFS) and overall survival (OS).

OUTLINE: Cryopreserved AML specimens are analyzed for pStat3 and pStat5 levels, response to cytokine levels, and expression level of proteins known to influence stat activity by flow cytometry and western blot assays. Results are also compared with prognostic variables determined in CCG-291 study, including age, race, WBC, and cytogenetic risks.

Enrollment

150 estimated patients

Sex

All

Ages

Under 30 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS: